FY2025 Earnings Estimate for DexCom Issued By William Blair

DexCom, Inc. (NASDAQ:DXCM) – Equities researchers at William Blair lowered their FY2025 earnings estimates for shares of DexCom in a research note issued on Friday, October 31st. William Blair analyst B. Vazquez now anticipates that the medical device company will earn $2.05 per share for the year, down from their prior forecast of $2.06. William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for DexCom’s current full-year earnings is $2.03 per share. William Blair also issued estimates for DexCom’s Q2 2026 earnings at $0.60 EPS, Q3 2026 earnings at $0.66 EPS, Q4 2026 earnings at $0.66 EPS, FY2026 earnings at $2.45 EPS, Q1 2027 earnings at $0.67 EPS, Q2 2027 earnings at $0.71 EPS, Q3 2027 earnings at $0.75 EPS and FY2027 earnings at $2.90 EPS.

DXCM has been the topic of several other research reports. Robert W. Baird set a $82.00 price target on DexCom in a research note on Friday. JPMorgan Chase & Co. cut their target price on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Friday. Royal Bank Of Canada reduced their price target on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a report on Friday. Citigroup dropped their price objective on shares of DexCom from $85.00 to $75.00 and set a “buy” rating on the stock in a research note on Friday. Finally, TD Cowen cut their price objective on shares of DexCom from $100.00 to $84.00 and set a “buy” rating on the stock in a report on Friday. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $89.33.

DexCom Trading Up 3.8%

Shares of NASDAQ DXCM opened at $60.43 on Monday. DexCom has a twelve month low of $56.44 and a twelve month high of $93.25. The firm has a market cap of $23.70 billion, a PE ratio of 41.97, a price-to-earnings-growth ratio of 1.43 and a beta of 1.47. The business has a fifty day simple moving average of $70.63 and a two-hundred day simple moving average of $77.97. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. The firm had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.DexCom’s quarterly revenue was up 21.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.45 earnings per share. DexCom has set its FY 2025 guidance at EPS.

Insider Activity

In other DexCom news, Director Kyle Malady sold 667 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the sale, the director directly owned 22,667 shares in the company, valued at $1,832,853.62. This trade represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction on Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the completion of the transaction, the director directly owned 51,121 shares in the company, valued at $4,143,868.26. This represents a 5.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 5,383 shares of company stock worth $434,274. 0.32% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in DXCM. Andra AP fonden acquired a new position in shares of DexCom during the second quarter valued at about $26,000. Twin Peaks Wealth Advisors LLC acquired a new stake in DexCom in the 2nd quarter worth approximately $26,000. SJS Investment Consulting Inc. grew its position in DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after purchasing an additional 384 shares during the last quarter. Zions Bancorporation National Association UT acquired a new position in DexCom during the 1st quarter valued at approximately $27,000. Finally, Financial Consulate Inc. acquired a new position in DexCom during the 3rd quarter valued at approximately $29,000. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.